Palazzuoli, Alberto
Iacoviello, Massimo http://orcid.org/0000-0001-9613-5062
Article History
Accepted: 5 April 2022
First Online: 6 May 2022
Change Date: 4 September 2022
Change Type: Update
Change Details: The original version of this paper was updated to add funding note.
Declarations
:
: The manuscript does not contain clinical studies or patient data.
: M. Iacoviello received honoraria as a consultant in advisory boards from AstraZeneca, Boehringer Ingelheim, Lilly, Merck Serono, Novartis, and Vifor Pharma. A. Palazzuoli received honoraria as a consultant from Menarini and Novartis.